Moderna exceeds revenue expectations by over USD 700m

The US-based vaccine maker only has a single approved product on the market, which has just booked a USD 4.5bn revenue in the second quarter.

Photo: Dado Ruvic/REUTERS / X02714

US-based vaccine maker Moderna generated USD 4.75bn in revenues during the second quarter of 2022, of which USD 4.5bn came from a single product: its Covid-19 vaccine.

Based on Bloomberg News’s surveys, the analyst consensus estimate for the firm’s revenue was only USD 4.02bn – meaning they were off target by roughly USD 700m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs